📊 CRLBF Key Takeaways
Is Cresco Labs Inc. (CRLBF) a Good Investment?
Cresco Labs' financial data is completely unavailable in SEC EDGAR, with only 1 metric available and no data freshness information, indicating potential non-compliance, delisting status, or failure to file required reports. The absence of any fundamental metrics (revenue, profitability, assets, cash flow) makes fundamental analysis impossible and presents severe information risk to investors.
Cresco Labs still generates meaningful gross profit and positive operating cash flow, but the core fundamental trend is weak: revenue fell from $770.9M in 2023 to $724.3M in 2024 and $655.8M in 2025, while 2025 operating income turned negative and net losses widened. The balance sheet remains heavily leveraged with cash down to $57.9M, shareholders' equity compressed to $252.5M, and large impairment charges signaling weaker asset quality and pressured growth economics.
Why Buy Cresco Labs Inc. Stock? CRLBF Key Strengths
- No strengths identified
- Gross margin remained relatively solid at about 49.5% in 2025 despite industry pricing pressure
- Operating cash flow stayed positive at $72.9M in 2025, indicating the business still converts part of earnings into cash
- Debt was refinanced and reduced, extending major maturity to 2030 and improving near-term refinancing risk
CRLBF Stock Risks: Cresco Labs Inc. Investment Risks
- No financial data available - unable to assess revenue, profitability, or financial position
- Likely non-filer or delisted status given absence of recent SEC filings with substantive financial information
- Zero insider filings in last 90 days suggests potential company distress or inactive management trading
- Medicinal chemicals sector subject to regulatory uncertainty, particularly cannabis-related companies facing federal legal restrictions
- Insufficient data to evaluate liquidity, solvency, operational efficiency, or growth prospects
- Revenue has declined for three straight years, pointing to weak growth quality and ongoing competitive price compression
- Net losses remain persistent and worsened to about $135.4M in 2025, with negative operating income and poor interest coverage
- Financial health is strained by high leverage, lower cash balances, falling equity, and large 2025 impairment charges
Key Metrics to Watch
- SEC filing status and regulatory compliance
- Revenue and gross margin (if company becomes current filer)
- Cash position and working capital adequacy (if financial data becomes available)
- Revenue stabilization and operating margin recovery
- Operating cash flow and ending cash relative to debt and tax obligations
Cresco Labs Inc. (CRLBF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CRLBF Profit Margin, ROE & Profitability Analysis
CRLBF vs Materials Sector: How Cresco Labs Inc. Compares
How Cresco Labs Inc. compares to Materials sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cresco Labs Inc. Stock Overvalued? CRLBF Valuation Analysis 2026
Based on fundamental analysis, Cresco Labs Inc. has mixed fundamental signals relative to the Materials sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cresco Labs Inc. Balance Sheet: CRLBF Debt, Cash & Liquidity
CRLBF Revenue Growth, EPS Growth & YoY Performance
CRLBF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cresco Labs Inc. (CIK: 0001832928)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRLBF
What is the AI rating for CRLBF?
Cresco Labs Inc. (CRLBF) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRLBF's key strengths?
Claude: . ChatGPT: Gross margin remained relatively solid at about 49.5% in 2025 despite industry pricing pressure. Operating cash flow stayed positive at $72.9M in 2025, indicating the business still converts part of earnings into cash.
What are the risks of investing in CRLBF?
Claude: No financial data available - unable to assess revenue, profitability, or financial position. Likely non-filer or delisted status given absence of recent SEC filings with substantive financial information. ChatGPT: Revenue has declined for three straight years, pointing to weak growth quality and ongoing competitive price compression. Net losses remain persistent and worsened to about $135.4M in 2025, with negative operating income and poor interest coverage.
What is CRLBF's revenue and growth?
Cresco Labs Inc. reported revenue of N/A.
Does CRLBF pay dividends?
Cresco Labs Inc. does not currently pay dividends.
Where can I find CRLBF SEC filings?
Official SEC filings for Cresco Labs Inc. (CIK: 0001832928) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRLBF's EPS?
Cresco Labs Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CRLBF a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cresco Labs Inc. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CRLBF stock overvalued or undervalued?
Valuation metrics for CRLBF: ROE of N/A (sector avg: 14%), net margin of N/A (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy CRLBF stock in 2026?
Our dual AI analysis gives Cresco Labs Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CRLBF's free cash flow?
Cresco Labs Inc.'s operating cash flow is N/A, with capital expenditures of N/A.
How does CRLBF compare to other Materials stocks?
Vs Materials sector averages: Net margin N/A (avg: 10%), ROE N/A (avg: 14%), current ratio N/A (avg: 1.6).